Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000482 | 0.86 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1EPHX1PARP10PARP14 | |
| SCHEMBL16003020 | 0.85 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1EPHX1PARP10ACHE | |
| SCHEMBL23417314 | 0.84 | HPGD (0.64) | L3MBTL1EPHX1EPHX2ALDH1A1MGLL | |
| SCHEMBL16002875 | 0.84 | MGLL (0.63) | MGLL | |
| SCHEMBL23682828 | 0.83 | ALDH1A1 (0.68) | L3MBTL3L3MBTL1ALDH1A1MGLLHPGD | |
| SCHEMBL13202940 | 0.83 | MGLL (0.62) | L3MBTL1ALDH1A1MGLL | |
| SCHEMBL16002882 | 0.82 | EPHX1 (0.56) | L3MBTL3L3MBTL1EPHX1ACHEALDH1A1 | |
| SCHEMBL10293612 | 0.82 | EPHX1 (0.71) | L3MBTL3L3MBTL1EPHX1EPHX2ACHE | |
| SCHEMBL14786240 | 0.82 | ALDH1A1 (0.62) | L3MBTL3L3MBTL1PARP10PARP14ALDH1A1 | |
| SCHEMBL16003032 | 0.81 | LMNA (0.63) | L3MBTL3L3MBTL1EPHX1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | L3MBTL3 4679/4885L3MBTL1 3948/4885EPHX1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.